Satsuma Pharmaceuticals to Present at Upcoming Healthcare Conferences

Rhea-AI Summary

Satsuma Pharmaceuticals, a clinical-stage biopharmaceutical company, announced CEO John Kollins will present at two upcoming healthcare conferences. The Credit Suisse 30th Annual Healthcare Conference is scheduled for November 10, 2021, from 3:30 to 4:10 p.m. ET, followed by the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, from 11:20 to 11:40 a.m. ET. Both events will allow investors to participate via webcast and schedule one-on-one meetings. Satsuma is developing STS101, a nasal powder formulation for treating migraines, showing promise in its delivery and efficacy.

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present in the month of November at the following conferences and invites investors to participate via webcast and in virtual one-on-one meetings. Please see additional details below:

Credit Suisse 30th Annual Healthcare Conference
Date:	Wednesday, November 10th
Time:	3:30 to 4:10 p.m. ET (virtual event)
Presenter:	John Kollins, President & CEO of Satsuma Pharmaceuticals
Webcast:	Registration Link – Click Here
	* a replay will be available following the presentation

Please contact your representative at Credit Suisse to schedule a virtual one-on-one meeting with Satsuma Pharmaceuticals during the respective conference.

For more information about the Credit Suisse 30^th Annual Healthcare Conference, please refer to the conference website.  

Evercore ISI 4th Annual HealthCONx Conference
Date:	Tuesday, November 30th
Time:	11:20 to 11:40 a.m. ET (virtual event)
Presenter:	John Kollins, President & CEO of Satsuma Pharmaceuticals
Webcast:	Registration Link – Click Here
	* a replay will be available following the presentation

Please contact your representative at Evercore ISI to schedule a virtual one-on-one meeting with Satsuma Pharmaceuticals during the respective conference.

For more information about the Evercore ISI 4^th Annual HealthCONx Conference, please refer to the Evercore ISI conference website.

About Satsuma Pharmaceuticals and STS101

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine. STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device.  STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and injectable dosage forms lack. Satsuma’s dry powder DHE formulation has demonstrated fast absorption, rapid achievement of high DHE plasma concentrations which Satsuma believes is necessary for early efficacy, and sustained plasma levels over time with low dose to dose variability. STS101 also now incorporates an improved 2nd-generation nasal delivery device designed to provide more consistent nasal dosing, irrespective of user administration technique. Although DHE has long been recommended in published migraine treatment guidelines as a first-line acute treatment option for migraine and has significant advantages versus other anti-migraine treatments for many patients, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration processes and/or sub-optimal clinical performance, have limited the widespread use of DHE. Featuring a compact and convenient dosage form, STS101 is designed to overcome these shortcomings and provide patients an improved therapeutic solution for acutely treating migraines that consistently delivers robust clinical performance.

Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.

INVESTOR AND CORPORATE CONTACTS:         

Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com 

Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com 

FAQ

What is Satsuma Pharmaceuticals presenting at the Credit Suisse 30th Annual Healthcare Conference?

Satsuma Pharmaceuticals will have CEO John Kollins presenting on November 10, 2021, at 3:30 p.m. ET, discussing their migraine treatment STS101.

When is Satsuma Pharmaceuticals' presentation at the Evercore ISI 4th Annual HealthCONx Conference?

The presentation is set for November 30, 2021, at 11:20 a.m. ET, featuring CEO John Kollins discussing STS101.

What is STS101 by Satsuma Pharmaceuticals?

STS101 is a novel nasal powder formulation of dihydroergotamine for acute migraine treatment, designed for quick self-administration and enhanced efficacy.

How can investors participate in Satsuma Pharmaceuticals' conference presentations?

Investors can join via webcast and arrange one-on-one meetings with Satsuma Pharmaceuticals' representatives at both conferences.

Where can I find more information about Satsuma Pharmaceuticals?

More details can be found on Satsuma Pharmaceuticals' official website at www.satsumarx.com.